These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27306812)

  • 1. [Economic Loss of Remaining Contents in Molecular Target Drug Preparation and the Simulation for Cost Saving].
    Usami E; Kimura M; Fukuoka T; Okada K; Yoshimura T
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):743-7. PubMed ID: 27306812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug Vial Optimization(DVO)for Anti-Cancer Drugs].
    Iwamoto T
    Gan To Kagaku Ryoho; 2017 May; 44(5):353-356. PubMed ID: 28536326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Era of personalized medicine may herald end of soaring cancer costs.
    Keogh B
    J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
    [No Abstract]   [Full Text] [Related]  

  • 6. Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis.
    Tirelli U; Berretta M; Bearz A; Carbone A
    Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1355-6. PubMed ID: 22195374
    [No Abstract]   [Full Text] [Related]  

  • 7. Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil.
    Clark L; Castro AP; Fortes AF; Santos F; Clark O; Engel T; Pegoretti B; Teich V; Vianna D; Puty F
    Value Health; 2011; 14(5 Suppl 1):S82-4. PubMed ID: 21839906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Verification of reduction in preparation time and cost of cyclophosphamide when using the closed-system drug transfer device].
    Ikeno Y; Arii D; Nakajima H; Murooka K; Nojima M; Kidokoro A
    Gan To Kagaku Ryoho; 2014 May; 41(5):611-5. PubMed ID: 24917007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
    Nerich V; Borg C; Villanueva C; Thiery-Vuillemin A; Helias P; Rohrlich PS; Demarchi M; Pivot X; Limat S
    J Oncol Pharm Pract; 2013 Mar; 19(1):8-17. PubMed ID: 22623276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital.
    Matsuo K; Nomura H; Uchiyama M; Miyazaki M; Imakyure O
    BMC Health Serv Res; 2020 Nov; 20(1):1017. PubMed ID: 33167996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of a standardised pharmacist check of medical orders prior to preparation of anticancer drugs to reduce drug wastage.
    Yamada H; Kobayashi R; Shimizu S; Yamada Y; Ishida M; Shimoda H; Kato-Hayashi H; Fujii H; Iihara H; Tanaka H; Suzuki A
    Int J Clin Pract; 2020 Apr; 74(4):e13464. PubMed ID: 31830345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness analysis of 5-HT3 receptor antagonist drugs in cancer chemotherapy].
    Ishimaru H; Takayama S; Shiokawa M; Inoue T
    Gan To Kagaku Ryoho; 2008 Apr; 35(4):619-23. PubMed ID: 18408430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
    Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
    Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Examination of Actual Medical Material Cost and Cost Reduction Related to Exposure Prevention in the Preparation of Anticancer Drugs].
    Moriya A; Usami E; Hirose T; Takenaka S; Asano H; Okada K; Adachi S; Yoshimura T
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1281-1286. PubMed ID: 31501370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. It is not only the empty vials that go into the garbage can during chemotherapy drugs preparation: a cost analysis of unused chemotherapy drugs in cancer treatment.
    Ata A; Abali H; Yengel E; Arican A
    J BUON; 2012; 17(4):781-4. PubMed ID: 23335541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic evaluation for the prevention of cervical cancer by vaccination--from perspective of health insurance society and industry].
    Kawabayashi Y; Furuno M; Uchida M; Kawana T
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):493-8. PubMed ID: 23848018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
    Francis SM; Heyliger A; Miyares MA; Viera M
    J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Centralization impact and cost-saving study in a Moroccan hospital's centralized unit of chemotherapy preparation.
    Adade CA; Benabbes M; Belahcen MJ; Rahali Y
    J Oncol Pharm Pract; 2020 Oct; 26(7):1630-1636. PubMed ID: 32046581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost savings from dose rounding of biologic anticancer agents in adults.
    Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
    J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.